Grand Yangtze Capital
VC Fund
Shanghai, China
Grand Yangtze Capital is an investment firm focused principally on equity investments in growth and expansion stage enterprises in China. They have been managing 7 PE and VC funds since 2007 and have deployed over 4 billion RMB. Grand Yangtze Capital has invested in over 40 companies, among which 8 companies went public, and several others weremerged or acquired, e.g. Sino-Crystal (300064), Shuanghuan(002472), Hainan Rubber(601118), HLBN(300291), ZMJ(601717), China UMS, ZBT Pharma, ELLASSAY(603808), B-Soft(300451), Guochuang Software(300520), YMatou, Pharma Block, etc.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 23%
- Fund size:
- $88M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Grand Yangtze Capital invests in
Stages Grand Yangtze Capital invests in
Countries Grand Yangtze Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Manufacturing 10 (32%)
- Biotechnology 4 (13%)
- Software 3 (10%)
- Health Care 3 (10%)
- Finance 2 (6%)
Stage
- Series A 12 (39%)
- Series B 9 (29%)
- Angel 3 (10%)
- Funding Round 2 (6%)
- Series C 1 (3%)
Country
- China 27 (87%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chunyi Li
Founding Partner, President
|
Founding Partner, President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Chengdu Pukang Biotechnology Co.
|
Chengdu Pukang Biotechnology Co., Ltd specializes in the development, production, and supply of high-purity single molecular PEG series derivatives, polypeptide long-acting drug side chains, and their intermediates. The company focuses on serving the pharmaceutical industry with a range of chemical supplies that are crucial for drug development andmanufacturing processes. With a professional R&D team, Chengdu Pukang Biotechnology is dedicated to advancing pharmaceutical intermediates technology and providing solutions that meet the evolving needs of the healthcare sector. The company's commitment to research and development is evident in its continuous efforts to innovate and improve its product offerings to support the pharmaceutical industry. | Series B / Jun 06, 2024 | |
Bitong Semiconductor
|
Bitong Semiconductor is a full-service high-tech company that specializes in installing and troubleshooting equipment. | $70.5M / Venture - Series Unknown / Nov 23, 2023 | |
Diallebo
|
Diallebo is a biotech company that focuses on R&D, manufacturing & sales of laboratory testing products for autoimmune diseases and neurological diseases. | $13.7M / Series A / Sep 15, 2023 | |
Eaglenos
|
Eaglenos is an IVD company that specialises in medical POCT, home health care devices, and health management systems. It focuses on chemistry, materials, electronics, software, machinery, and biomedical engineering. It helps in the advancement of electrochemistry, microfluidics, signal acquisition, and automation technologies. | $21.2M / Series A / May 29, 2023 | |
Kingdee Invoice Cloud
|
Kingdee Invoice Cloud focuses on controlling invoice data and managing accounting vouchers. It has developed three key cloud services, including smart bill cloud, electronic accounting file cloud, and reimbursement robot. These services make extensive use of cutting-edge technologies like artificial intelligence, blockchain, digital twins, and theInternet of Things. | Series A / May 18, 2023 | |
TBSTest Technology
|
Yuexin Technology is a semiconductor test equipment developer specializing in R&D, production and sales of ultra-large-scale integrated circuit test equipment (ATE). Its main product is SOC test equipment, which is mainly for enterprise users of integrated circuit design, production, packaging and testing. Integrated circuit test equipment andsolutions. | $74.7M / Series C / Jun 24, 2022 | |
Hai Guanjia
|
YunLSP is the developer of SaaS cloud collaboration systems and tools designed for the logistics enterprise system. | $15M / Series B / Jun 06, 2022 | |
Maibang Bio
|
Maibang Bio is a cell culture medium product developer, focusing on the research and development of high-end chemically defined. | $15.7M / Series B / Apr 15, 2022 | |
Yaotan Pharmaceutical
|
Yaotan Pharmaceutical is a comprehensive one-stop CDMO service provider. | $29.9M / Series A / Mar 29, 2022 | |
|
Vision Semiconductor Technology
|
The founding team of Vipas Semiconductor is composed of high-tech technical experts and market management experts from home and abroad. Relying on Nanjing University's independent innovation of vertical charge transfer imaging device (VPS) technology, it focuses on a new generation of new sensor imaging chip technology products. A high-techcompany that develops and manufactures. | $15.7M / Series A / Nov 29, 2021 | |
| See all 31 investments → | |||
Co-Investors
SDIC Venture Capital
4 deals together
Cowin Venture
2 deals together
Huatai Zijin Investment
2 deals together
Sangel Capital
2 deals together
October Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Grand Yangtze Capital invest in?
Grand Yangtze Capital invests primarily in Manufacturing, Biotechnology and Software startups, most often at Series A and Series B stage. Most of the 31 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Grand Yangtze Capital?
Public channels for Grand Yangtze Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Grand Yangtze Capital?
The team at Grand Yangtze Capital includes Chunyi Li (Founding Partner, President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
